Addition of prophylactic gastrojejunostomy to hepaticojejunostomy significantly reduces gastric outlet obstruction in people with unresectable periampullary cancer
Executive Summary
The surgical management of unresectable periampullary cancer remains a critical area of palliative care. While biliary-enteric bypass is a standard procedure to address obstructive jaundice, the inclusion of a prophylactic gastrojejunostomy (GJ) to prevent future gastric outlet obstruction (GOO) has historically been a point of surgical controversy.
Recent high-level clinical evidence, specifically from a multicenter randomized controlled trial (RCT) in the Netherlands and a prior single-institution trial at Johns Hopkins Hospital, definitively supports the addition of a retrocolic gastrojejunostomy. Key findings include:
Significant Reduction in Obstruction: The addition of a prophylactic GJ reduces the incidence of symptomatic gastric outlet obstruction from approximately 41% to 6%.
Reduced Need for Re-operation: Only 3% of patients receiving a double bypass required re-operation for obstruction, compared to 21% in those receiving only a biliary bypass.
No Increase in Morbidity or Mortality: The addition of the second bypass does not significantly increase hospital stay, morbidity (including delayed gastric emptying), or mortality rates.
Quality of Life Maintenance: Quality of life assessments indicate no adverse impact from the additional procedure.
The combined evidence indicates that prophylactic gastrojejunostomy should be considered the standard of care for patients found to have unresectable disease during exploratory laparotomy.
Background and Nature of the Clinical Problem
Periampullary adenocarcinoma includes four distinct pathologic entities: cancers of the head of the pancreas, the ampulla of Vater, the distal bile duct, and the duodenum. Pancreatic adenocarcinoma is the most common form and is the fifth leading cause of cancer death in the United States, accounting for over 30,000 deaths annually.
The Challenge of Unresectability
Surgical resection (pancreaticoduodenectomy) is the only potential cure. However, despite improvements in pre-operative staging, surgical exploration remains the "gold standard" for determining resectability. Approximately 25% to 75% of patients who undergo surgery with the intent to resect are found to have unresectable disease. In these cases, the surgeon’s focus shifts to appropriate palliation.
The Controversy of Prophylactic Gastrojejunostomy
While biliary bypass is routinely performed to treat jaundice, the decision to perform a GJ in the absence of current obstruction has been debated due to:
Concerns regarding increased post-operative morbidity, particularly delayed gastric emptying.
The argument that limited long-term survival may eliminate the need for prophylactic measures.
Retrospective data showing that 13% to 21% of patients eventually require GJ before death, with re-operation carrying high mortality rates (approaching 25%).
Detailed Analysis: The Netherlands Multicenter Trial (Van Heek et al.)
A prospective randomized multicenter trial was conducted across four centers in the Netherlands between December 1998 and March 2002 to assess the efficacy of prophylactic GJ.
Study Design and Participants
The trial included 70 participants with pathologically proven unresectable periampullary cancer.
Tumor Location: 87% were in the pancreatic head.
Disease State: 52% had local vascular invasion, 45% had metastases, and 3% had both.
Methodology: Participants were randomized during surgery to receive either a Double Bypass (hepaticojejunostomy + retrocolic gastrojejunostomy) or a Single Bypass (hepaticojejunostomy alone).
Comparative Outcomes
The trial was terminated early following a planned interim analysis at 50% recruitment due to the significant therapeutic benefits observed in the double bypass group.
Table 1: Primary and Secondary Clinical Outcomes
Table 2: Adverse Effects and Morbidity
Cross-Validation: The Johns Hopkins Hospital Trial
The findings of the Netherlands study correlate strongly with a prior single-center RCT conducted at Johns Hopkins Hospital over a five-year period involving 87 randomized patients.
Morbidity and Mortality: No post-operative deaths occurred in either group. Morbidity rates were nearly identical (32% for GJ vs. 33% for no GJ).
Hospital Stay: Length of stay was comparable (8.5 days for GJ vs. 8.0 days for no GJ).
Obstruction Rates: 0% of the prophylactic GJ group developed late GOO, whereas 19% of the group without prophylactic GJ developed obstruction requiring intervention (p < 0.01).
Timing: The median time between initial surgery and the need for therapeutic intervention for obstruction was two months.
Clinical Implications and Conclusions
The synthesis of Level I clinical evidence from these two major trials provides a definitive answer to the role of prophylactic gastrojejunostomy.
Standard of Care: Prophylactic gastrojejunostomy is strongly indicated for patients with unresectable periampullary carcinoma found during exploratory laparotomy.
Surgical Efficacy: The procedure significantly decreases the incidence of late-stage gastric outlet obstruction and the subsequent need for high-risk re-operations.
Safety Profile: The addition of a retrocolic gastrojejunostomy does not increase perioperative mortality or significantly increase morbidity. While some reports suggested concerns over delayed gastric emptying, the randomized trials show no statistically significant difference between single and double bypass groups.
Quality of Life: Careful analysis using EORTC-C30 and Pan26 questionnaires confirms that the additional bypass does not diminish the patient's quality of life at 4 or 12 months post-operation.
In summary, for surgeons encountering unresectable periampullary tumors during laparotomy, the double bypass approach (biliary and gastric) offers superior palliation with no significant increase in surgical risk.
